Graduate School of Pharmaceutical Sciences, Kyushu University 62, Fukuoka, Japan (H.Y., H.M., K.T., S.M., M.Y., Y.I., K.O.); and
Department of Environmental Health, University of Washington, Seattle,
Washington (C.J.O.)
The Qdj:Sprague-Dawley (SD) rat is a mutant strain lacking in
phenobarbital (PB)-mediated induction of CYP2B2. The presence of
interindividual differences in the hepatic content of CYP2B proteins
and testosterone 16
-hydroxylase activity demonstrated that the
breeding colony of Qdj:SD rats involves normal (+/+) and intermediate
(+/
) phenotypes as well as mutant (
/
)-type rats. Although
PB-treated Qdj:SD (
/
) rats expressed CYP2B1 normally, testosterone
16
-hydroxylase activity in these rats was quite low. Analysis of
regioselective metabolism of testosterone and 4-hydroxybiphenyl
glucuronidation demonstrated normal catalytic activities associated
with other forms of cytochrome P450s, including CYP2A, -2C, and -3A, as
well as PB-inducible UDP-glucuronosyltransferase in Qdj:SD
(
/
) rats. There were no serious mutations in the exons of the
CYP2B1 gene in Qdj:SD (
/
) rats, demonstrating that
this gene codes a functional CYP2B1. These observations suggest that CYP2B1 needs the interaction with CYP2B2 to exert the full function. The CYP2B2 gene in Qdj:SD (
/
) rats was the same as
that in wild-type (+/+) rats in its length of the region containing all
exon/introns and 5'-upstream up to
2.3 kilobase pairs. Malignant
mutation such as stop codon formation was not observed in the exons,
and no mutation was detected in the region containing the PB-responsive unit. These results strongly suggest that impaired induction of CYP2B2
in Qdj:SD (
/
) rats is attributable either to mutation at the region
different from PB-responsive unit and exons or to absence or lowered
expression of trans-acting factor(s) necessary for gene regulation.
 |
Introduction |
Hepatic
cytochromes P450 belonging to the CYP2B subfamily metabolize a wide
variety of xenobiotics as well as endogenous substances such as
steroids and fatty acids (Guengerich, 1987
; Oguri et al., 1994
). Of
members in the CYP2B subfamily, rat CYP2B1 and CYP2B2 are known to be
highly inducible by many compounds that have divergent chemical
structures (Waxman and Azaroff, 1992
) and have been studied extensively
both toxicologically and biologically. The mechanism by which PB
induces the CYP2B subfamily P450 is not completely understood (for
recent reviews, see Savas et al., 1999
; Waxman, 1999
). However, recent
results from Negishi and colleagues (Honkakoski et al., 1998
) have
demonstrated that a heterodimer of nuclear receptors CAR and RXR plays
a crucial role in the regulation of the CYP2B subfamily and that PB
recruits the CAR from cytosol to nucleus by mechanism(s) that may
involve a protein dephosphorylation event (Kawamoto et al., 1999
). The
transcriptional activation process likely involves CAR/RXR interaction
with a specific region of 5'-flanking gene sequence designated as the
PBREM. A recent report using a transgenic mouse model demonstrated that
mutation of the central NF1 motif within the CYP2B2 PBRU had
no major effect on the PB induction process (Ramsden et al., 1999
).
However, the role of potential protein-protein interactions within the
PBRU/PBREM still needs to be explored in more detail. [A specific
region located in 5'-upstream of the rat CYP2B2 gene that is
suggested to play a role in PB-mediated induction was designated the
PBRE (Trottier et al., 1995
) or PBRU (Stoltz et al., 1998
). The
analogous region found in mouse Cyp2b10 and human
CYP2B6 genes was designated the PBREM (Honkakoski and
Negishi, 1997
). In this article, we refer to this region in the
CYP2B2 gene as the PBRU.]
Hashimoto et al. (1988)
have reported that SD (Qdj:SD) rats being bred
in the Kyushu University animal colony were an abnormal strain because
CYP2B2 was not induced after PB treatment, although CYP2B1 was normally
PB-responsive. These investigators have also observed that the lack of
CYP2B2 mRNA elevation by PB pretreatment suggested a transcriptional
defect, that the phenotype lacking in response to PB-mediated induction
appeared to be recessive trait caused by a single gene mutation, and
that there was no mutation and/or deletion in the proximate
0.8 kbp
of the gene 5'-flanking sequence. This animal model may prove to be a
valuable tool for clarifying mechanisms underlying PB-mediated
induction. The mechanisms accounting for the lack of CYP2B2 induction
in these animals remain unknown. One possibility is that the
CYP2B2 gene in Qdj:SD rats has a defect(s) in its exon
structure, resulting in the production of abnormal protein. Therefore,
a primary objective of this study focused on this latter issue, and we
have completed sequencing of the exonic regions. Because the PBRU is
likely to be important for PB responsiveness, we also determined the
sequence of the CYP2B2 gene's upstream region containing
this response element.
CYP2B1 and CYP2B2 are closely related enzymes with similar catalytic
function (Guengerich, 1987
; Funae and Imaoka, 1993
). Because many
PB-like inducers reported thus far increase both P450s, the specific
contribution of each isoform to the drug-metabolizing process has not
been fully clarified. The Qdj:SD rats appeared to represent an
appropriate animal model for addressing this issue. Therefore, in the
current investigation we also estimated the function of hepatic CYP2B
P450s in PB-treated Qdj:SD rats. The results suggest that CYP2B1
synergizes with CYP2B2 in eliciting its maximal function.
 |
Experimental Procedures |
Materials.
The chemicals described below were purchased from
the sources indicated: sodium PB (Tokyo Chemical Industry, Co. Ltd.,
Tokyo, Japan), 4-hydroxybiphenyl (Wako Pure Chemical Industries, Co., Ltd., Osaka, Japan), and morphine hydrochloride (Takeda Chemical Industries, Ltd., Osaka, Japan). Standards of hydroxytestosterones were
kindly donated by Dr. T. Baba, Shionogi Pharmaceutical Co. (Osaka,
Japan). Rabbit anti-CYP2B1/2 antibody was prepared in this laboratory.
Anti-CYP3A antibody, which cross-reacts with CYP3A1 and CYP3A2, was
purchased from Daiichi Pure Chemicals, Co. (Tokyo, Japan). [It is well
established that a major glucocorticoid-inducible isoform of the CYP3A
subfamily is CYP3A1. Later it was suggested to designate this form
CYP3A23 (Komori and Oda, 1994
). However, to avoid confusion, we refer
to the PB-inducible isoform using the more conventional term CYP3A1 in
this article, consistent with the terminology used in a large number of
previous reports.]
Alkaline phosphatase-conjugated anti-rabbit IgG antibody was obtained
from Zymed Laboratories, Inc. (San Francisco, CA). Oligonucleotide primers for PCR and/or sequencing were supplied by Sawady Technology Co. (Tokyo, Japan) or Life Technologies Co. (Tokyo, Japan). All other
chemicals were of the highest quality available commercially.
Animals, Treatment, and Preparation of Microsomes and Genomic
DNA.
Male Qdj:SD rats weighing 120 to 150 g were obtained
from the animal facility at Kyushu University. This strain was being bred by crossing female and male parental rats randomly selected from a
colony. Reference animals, male Crj:SD rats, with the same body
weight as the Qdj:SD rats were purchased from Charles River Japan
(Kanagawa, Japan). Rats were treated (i.p.) once a day with sodium PB
at a dose of 80 mg/kg/ml saline for 4 consecutive days. Control rats
were given saline alone. The animals were fasted overnight after the
last treatment, and the livers were removed. A portion (1 g) of each
liver was stored at
80°C, and genomic DNA was extracted using
established methods (Maniatis et al., 1989
). Microsomes were prepared
from the remaining liver using methods described elsewhere (Yamada et
al., 1993
) and stored at
80°C.
Immunoblotting.
Sodium dodecyl sulfate-polyacrylamide gel
(7%) electrophoresis was performed according to Laemmli's procedures
(1970)
. In all experiments, hepatic microsomes consisting of 9 µg of
protein were loaded and electrophoresed. The proteins in the gel were transferred electrically to a polyvinylidene difluoride membrane using
reported methods (Towbin et al., 1979
) and then reacted with rabbit
anti-CYP2B1/2 antibody. The band associated with the antibody was
visualized using the method of Blake et al. (1984)
, using alkaline
phosphatase-conjugated anti-rabbit IgG antibody.
Assays and Statistical Analysis.
Hepatic microsomal
activities of testosterone metabolism (Shinohara et al., 1997
),
4-hydroxybiphenyl glucuronidation (Bock et al., 1979
), and
morphine-3-glucuronidation (Hanioka et al., 1990
) were determined using
the methods indicated. Protein contents of the microsomal fractions
were determined according to established methods (Lowry et al., 1951
).
Statistical differences were calculated using ANOVA with the post hoc
test (Fisher's protected least-significant difference method).
PCR Amplification of CYP2B1/2 Genes.
Amplification of the CYP2B1 gene was performed by dividing
the gene into three segments (2B1/12 kbp, 2B1/6 kbp, and 2B1/7 kbp;
Fig. 1A). Similarly, four segments of the
CYP2B2 gene (2B2/PBRU, 2B2/12 kbp, 2B2/4 kbp, and 2B2/0.6
kbp; Fig. 1B) were separately amplified. Primer pairs used in these
PCRs are listed in Table 1. In a final
volume of 50 µl, the reaction mixture consisted of 500 ng of genomic
DNA; 200 nM each DNA primer; 2.5 mM MgCl2; 0.4 mM
each deoxynucleotide triphosphate; 2.5 U of Taq-polymerase (TaKaRa LA Taq; TAKARA Shuzo Co., Ltd., Shiga, Japan); and 5 µl of reaction buffer (10 × LA PCR Buffer II) supplied with the
Taq-polymerase kit. The reaction mixture was added to a
500-µl sterilized plastic tube with a cap, and a few drops of
mineral oil (Sigma Chemical Co., St. Louis, MO) were layered onto the
solution followed by cycling in a PCR tempcycler (ASTEC PC-700, ASTEC,
Fukuoka, Japan). The conditions of PCR were as follows: 2B1/12 kbp,
2B1/6 kbp, 2B1/7 kbp, 2B2/12 kbp, and 2B2/4 kbp, 98°C for 1 min
(94°C for 30 s and 64°C for 20 min) for 35 cycles and 72°C
for 10 min with a hold at 4°C; 2B2/0.6 kbp, 98°C for 1 min (94°C
for 30 s, 58°C for 1 min, and 65°C for 5 min) for 30 cycles
and 72°C for 10 min with a hold at 4°C; and 2B2/PBRU, 98°C for 1 min (94°C for 30 s, 56°C for 1 min, and 65°C for 5 min) for
30 cycles and 72°C for 10 min with a hold at 4°C. In the experiment
for nucleotide sequencing, the PCR product was purified using a
commercial column (GFX PCR DNA and Gel Band Purification kit; Amersham
Pharmacia Biotech Inc., Piscataway, NJ).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
PCR amplification of the CYP2B1 (A) and
CYP2B2 (B) genes. One of each of the primer pairs is
specific either to the CYP2B1 or to the CYP2B2
gene and selectively amplifies the target gene. See Table 1 for
additional information and the sequences of the primers. All PCR
products except "CYP2B1/12 kbp" were confirmed as the desired
products by sequence analysis of the gene exons that contain diagnostic
nucleotide substitutions distinguishing CYP2B1 and
CYP2B2 (Suwa et al., 1985 ). There is a major difference in
the length of first intron between CYP2B1 and
CYP2B2 (Suwa et al., 1985 ). The 12-kbp intron 1 region of CYP2B1 identified amplified products of
CYP2B1 gene.
|
|
Nucleotide Sequencing.
Exonic sequences of
CYP2B1/2 genes and a region containing the PBRU of the
CYP2B2 gene were determined by sequencing the PCR products
shown in Fig. 1 and Table 1. The intronic sequences of the
CYP2B1/2 genes have not been determined previously. In parallel with the current study, we sequenced the CYP2B2
gene cloned from an SD rat genomic library (pWE'-39E) (Ramsden et al., 1993
) and determined the area containing 7 kbp of 5'-upstream region
together with the exons/introns (S. Matsumoto, M. Yamamoto, H. Yamada,
C. J. Omiecinski, and K. Oguri, unpublished data). Some of the
sequencing primers used in this investigation were synthesized based on
this information (see legends to Tables 1 and 2). To minimize possible
PCR artifacts, the PCRs listed in Table 1 were performed at least four
times for each region, and these products were subjected separately to
DNA sequencing.
Nucleotide sequence was determined using the dideoxy termination
method (Sanger et al., 1977
), using a commercial kit (ABI PRISM Big Dye
Terminator Cycle Sequencing Ready Reaction kit, Perkin-Elmer Applied
Biosystems, Foster City, CA). The regions targeted for sequencing, the
templates (PCR product) used, and the primers used are summarized in
Table 2. Sequencing reaction was carried
out in a mixture (final volume, 20 µl) consisting of 5 ng/100 bp of
PCR product, 0.5 µM primer, and 5 µl of premixed reagent in the kit
containing deoxyribonucleotide triphosphate mixture,
fluorescent-labeled dideoxyribonucleotide triphosphate mixture,
Taq-polymerase, and the remaining reaction components. Reaction conditions were as follows: 96°C for 1 min (96°C for 30 s, 50°C for 15 s, and 60°C for 4 min) for 30 cycles
with a hold at 4°C. After the reactions the products were purified
using ethanol precipitation, and the precipitate was rinsed once with 70% (v/v) ethanol. The products were dissolved in 50 mM
ethylenediamine tetraacetic acid containing 20% (v/v) deionized
formamide, and the sequence was analyzed using an automatic DNA
se-quencer, PE Biosystems ABI 373, according to the manufacturer's
instrumentation protocols.
 |
Results |
Induction Pattern in Qdj:SD Rats and Phenotyping.
The
induction pattern of PB-inducible P450s and UGT in Qdj:SD rats was
compared with those in Crj:SD rats, a reference animal, by determining
hepatic microsomal activity of metabolism of testosterone, 4-hydroxybiphenyl, and morphine (Table
3). In a reference animal (Crj:SD rats),
PB treatment enhanced testosterone 6
- and 16
-hydroxylase activities, the markers for the CYP3A and -2B isoforms, respectively. Testosterone 6
-hydroxylase activity was also increased by PB treatment in all Qdj:SD rats, whereas for the 16
-hydroxylase, only a
minor increase was observed in one (rat 3) of four individual rats. The
activities of 4-hydroxybiphenyl and morphine glucuronidation were
increased with PB in both strains of rats including rat 3 of the Qdj:SD
rats. These results suggest that some individual Qdj:SD rats lack the
ability to induce the CYP2B isoform in response to PB treatment as
reported previously (Hashimoto et al., 1988
), that the whole colony of
these rats is not genetically homogeneous, and that impaired induction
is limited to the CYP2B subfamily.
View this table:
[in this window]
[in a new window]
|
TABLE 3
Change in the activity of hepatic microsomal drug-metabolizing enzymes
by treating Crj:SD and Qdj:SD rats with phenobarbital
Each value represents the mean ± S.E. of four rats. In the case
of PB-treated Qdj:SD rats, the values of four individual rats, which
were the mean of two or three assays, are shown. Relative activities to
the untreated (=100%) are shown in parentheses.
|
|
To better assess the nature of the abnormal phenotype in the Qdj:SD
rats, 10 rats were treated with PB and their expression patterns of
CYP2B1/2 and CYP3A1/2 were examined. In the immunoblot analysis (Fig.
2A), two bands of CYP2B1/2 were clearly
detected in four individual rats (rats 1, 3, 7, and 10). The remaining animals exhibited one band pattern owing to no or weak expression of
CYP2B2, although some of them (rats 2, 5, and 9) showed broader banding
than did the others (rats 4, 6, and 8). Differences in testosterone
16
-hydroxylase activity were correlated with the immunoblot data;
that is, very low activity was observed in three rats exhibiting a
sharp CYP2B band (Fig. 2, A and B). Immunoblot analysis with
anti-CYP3A1/2 antibody indicated that there was no difference between
individuals in the expression of this P450 (Fig. 2B). From these
results, approximately one-third of Qdj:SD rats were assumed to have an
abnormal phenotype lacking in PB-mediated induction of CYP2B2, with 10 rats subclassified into mutant-type [Qdj:SD (
/
); rats 4, 6, and
8], hetero-type [Qdj:SD (+/
); rats 2, 5, and 9], and wild-type
[Qdj:SD (+/+); rats 1, 3, 7, and 10] (Fig. 2A). Although the data are
not shown, neither CYP2B1 nor CYP2B2 was detected in the liver
microsomes from uninduced Qdj:SD (n = 4) and Crj:SD
(n = 4) rats by immunoblotting. Hepatic microsomal activity of regioselective metabolism of testosterone and
4-hydroxybiphenyl glucuronidation in each group of the Qdj:SD rats
treated with PB is shown in Fig. 3.
Mutant-type rats exhibited much lower activity of testosterone
16
-hydroxylase than did the hetero- and wild-type rats. Testosterone
16
-hydroxylation is known to be catalyzed by CYP2B1/2, although
CYP2C11 also has strong activity for this reaction (Funae and Imaoka,
1993
). Consistent with this profile, testosterone 16
-hydroxylase
activity was lower in the mutant-type rats than in the other two
phenotypes. Significant differences among the types were not observed
for other sites of hydroxylation of testosterone and 4-hydroxybiphenyl
glucuronidation, suggesting that the CYP2C11 (2
-hydroxylation),
CYP2A1 (7
-hydroxylation), CYP3A1/2 (6
-hydroxylation), and
PB-inducible UGT(s) are normally expressed or induced in Qdj:SD (
/
)
rats.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 2.
Interindividual difference in the expression of
CYP2B1/2 (A) and CYP3A (B) subfamilies in Qdj:SD rats pretreated with
phenobarbital. Ten rats were randomly chosen from a breeding colony and
treated with PB, and their contents of hepatic P450s were examined by
immunoblotting. In A, hepatic microsomal activity (nanomoles per minute
per milligram of protein) of testosterone 16 -hydroxylase was also
shown. Each bar represents the mean of two determinations. Based on the
difference in the intensity of the CYP2B2 immunoblot band and
testosterone hydroxylase activity, 10 rats were phenotyped as shown at
the top of the figure (see text for details).
|
|

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 3.
Hepatic microsomal activity of testosterone and
4-hydroxybiphenyl metabolism in Qdj:SD (+/+), (+/ ), and ( / ) rats
pretreated with phenobarbital. Hatched bars [(+/+), rats 1, 3, 7, and
10], open bars [(+/ ), rats 2, 5, and 9], and half-closed bars
[( / ), rats 4, 6, and 8] are the mean ± S.E. of three or
four individual rats indicated. See Fig. 2A for phenotyping. *,
significantly different from +/+ (P < .05). ,
significantly different from +/ (P < .05).
|
|
Structural Analyses of CYP2B1/2 Genes.
The size
and sequence of CYP2B2 and -2B1 genes in Qdj:SD
rats were compared with those in Crj:SD rats. To this end, the
CYP2B1/2 genes were selectively amplified by PCR, by using
specific primers for each gene (Table 1). Because the sequence homology
between CYP2B2 and -2B1 genes decreases markedly
in the upstream region far from
2.3 kbp, primer G is highly specific
for the amplification of "2B2/PBRU". A number of other primers were
designed by choosing regions in which differences exist between
CYP2B1 and -2B2 genes (see the legend to Table
1). Two PCR products from the CYP2B2 gene, 2B2/12 kbp and
2B2/4 kbp (Fig. 1), were the same length in both Qdj:SD (
/
) and
Crj:SD rats (Fig. 4). The identity of these products as CYP2B2, and not as CYP2B1, was
confirmed by subjecting the samples to sequencing of the exonic regions
(data not shown). This observation indicates that the CYP2B2
gene of Qdj:SD (
/
) rats does not have any large deletion and/or
insertion. To further probe potential mechanisms accounting for the
absence of the CYP2B2 gene product in Qdj:SD (
/
) rats
after PB treatment, the sequences of the upstream regulatory regions as
well as all exonic sequences were determined (Table
4). Interestingly, the sequence spanning
2319 to
1640 bp and containing the PBRU
(
2315GATCGTGGA ... CTGGGTGATC
2153) (Trottier et al., 1995
; Stoltz
et al., 1998
) was identical between Qdj:SD (
/
) and Crj:SD rats. As
for the exons, seven nucleotide alterations were detected in comparison
with the sequences reported previously. However, there were no sequence
differences between mutant-type and wild-type Qdj:SD rats. None of
seven base changes coded for stop-codons, and four were silent
mutations. Three mutations coded for amino acid substitutions, with two
(mutations at third and ninth exons) located in substrate recognition
sites 1 and 6, respectively. The GT-AG rule was confirmed in each
exon-intron junction (data not shown).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 4.
Agarose gel electrophoresis of the PCR product
amplified for the CYP2B2 gene present in Qdj:SD ( / ) and
Crj:SD rats. See Fig. 1 and Table 1 for the region amplified. A portion
of the PCR reaction mixture was loaded, electrophoresed in a 0.6%
agarose gel, and stained with ethidium bromide.
|
|
As described, PB-treated Qdj:SD (
/
) rats exhibited a strikingly low
activity of testosterone 16
-hydroxylation. However, this observation
is puzzling because CYP2B1 exhibits strong testosterone 16
-hydroxylase activity and is induced normally in these rats. One
possible explanation for this observation is that in Qdj:SD (
/
)
rats, not only is the CYP2B2 gene altered, but
CYP2B1 may also harbor defects in exon sequence, resulting
in the production of a protein with compromised activity. Therefore, we
sequenced the exons of CYP2B1 as well as the
CYP2B2 gene in this study. Two nonsynonymous mutations were
detected in comparison with the reported sequences (Table
5). However, the two encoded amino acid
substitutions were the same between the mutant- and wild-type rats,
suggesting that the CYP2B1 gene in Qdj:SD (
/
) rats does not contain deleterious mutations within its exonic structure.
 |
Discussion |
Since its discovery, the abnormal PB-CYP2B phenotype has been
assumed to be present in the whole colony of Qdj:SD rats at Kyushu
University. However, during breeding for the past 12 years, mating between mutant-type rats and rats with normal character would
have occurred. Breeding experiments by the discoverers of this
phenomenon indicated that the phenotype of the offspring (filial
generation 1, or F1) generated by mating Qdj:SD
rats with normal SD rats was normal (Hashimoto et al., 1988
).
Furthermore, they reported only two phenotypes in the
F2 generation. From these observations, the
mutant character in the Qdj:SD rats had been suggested to be a
recessive trait. However, an intermediate phenotype was observed in the
colony of Qdj:SD rats analyzed in this study. The reason for the
inconsistency between these studies is unknown, but it might be
attributable to the difference in the sensitivity and/or accuracy of
the phenotyping methods; e.g., the earlier researchers phenotyped rats
by determining CYP2B2 mRNA levels after PB treatment using assays that
might not have been highly quantitative.
The coding regions of the CYP2B2 gene in the mutant-type
Qdj:SD rats were sequenced in this study, but no defects were
discovered that would be anticipated to have any deleterious
consequences. In addition, conservation of the GT-AG rule was detected
in all exon-intron junctions. In general, the terminal base of the exon is G, which links to the GT of the intron. The structure of the CYP2B2 gene reported agrees with this rule (Suwa et al.,
1985
). At the end of fifth exon of the CYP2B2 gene in Qdj:SD
(
/
) rats, G was mutated to A (822G
A; nucleotide number is counted from the protein coding site of cDNA)
(see Table 4). However, genes not adhering to the ... G-GT...
junction structure have also been observed (Breathnach and Chambon,
1981
). Furthermore, the G/A mutation at the terminal base of the fifth
exon was also observed in the Qdj:SD (+/+) rats in which CYP2B2 is
normally induced using PB. The observation made here strongly suggests
that the structural gene in Qdj:SD (
/
) rats codes an expressible
and functional CYP2B2. A previous report suggesting that small
amounts of CYP2B2 protein exist in the liver of PB-pretreated Qdj:SD
rats supports this view (Hashimoto et al., 1988
). Mutant rats other
than the Qdj:SD strain having an abnormality in CYP2B2 expression have
already been reported (Rampersaud and Walz, 1987
). A large deletion in
the structural gene of CYP2B2 has been suggested as the
reason for the impaired expression in these rats (Omiecinski et al.,
1992
). Therefore, the mechanism causing a lack in PB-mediated induction
of CYP2B2 is quite different between Qdj:SD rats and other mutant rats
reported. Sequencing experiments also failed to detect mutations in the PBRU of Qdj:SD (
/
) rats. From the evidence presented here, the impaired induction of the CYP2B2 in Qdj:SD (
/
) rats is considered likely to involve one of the following mechanisms: 1) mutations within
5'-upstream gene regions not examined here or mutations within introns;
or 2) absence or lowered expression of trans-acting factor(s) necessary for gene regulation. If the former is the case,
then elements other than the PBRU would in effect be needed in
PB-mediated induction. An alternative consideration is whether trans-factors bound to the PBRU may interact with other
trans-factors associated with DNA at more distal sites.
Perhaps different trans-factor(s) are involved in the
induction of CYP2B1 versus CYP2B2, because Qdj:SD (
/
) rats exhibit
normal PB-mediated induction of the CYP2B1 gene. It has been
demonstrated that the RXR-pregnane X receptor complex plays an
important role in the induction of the CYP3A isoforms (Kliewer et al.,
1998
; Pascussi et al., 1999
). As shown in this investigation, CYP3A1
and CYP3A2 are normally induced using PB treatment in Qdj:SD (
/
)
rats. Thus, this observation does not support another possible
mechanism, that defects in RXR function are involved in the impaired
induction of CYP2B2 in these rats.
Abnormal expression and induction was rather specific to the CYP2B2 in
Qdj:SD (
/
) rats because other PB-inducible enzymes including CYP2A
and -3A subfamilies and UGT(s) were shown to be expressed normally.
However, in the progress of this study, we noted a possibility that
CYP2B1 induced with PB does not act effectively or has a defect in its
function in Qdj:SD (
/
) rats; that is, the activity of testosterone
16
-hydroxylase in PB-treated Qdj:SD (
/
) rats was shown to be
quite low even though the CYP2B1 protein level was increased markedly
using PB treatment. Sequencing experiments detected some nucleotide
substitutions in the CYP2B1 exons of these rats. However, it
is unlikely that these substitutions are responsible for the impaired
function. Of the two nonsynonymous mutations detected, one
(282Glu
Val) was located near substrate
recognition sites 4 (Goto, 1992
). However, this mutation is common in
both Qdj:SD (
/
) and (+/+) rats, and liver microsomes from the (+/+)
rats exhibit high levels of testosterone 16
-hydroxylation, as high
as Crj:SD rats. Based on the evidence from sequencing, the CYP2B1
protein expressed in Qdj:SD rats is suggested to have no defect in its
primary structure. Our results may suggest that the CYP2B1-CYP2B2
interaction is needed for the occurrence of maximal catalytic function
of the CYP2B1. Although this is speculative, the reason for the low
activity of testosterone 16
-hydroxylase in Qdj:SD (
/
) rats might
be attributable to a decreased interaction between CYP2B1 and CYP2B2, resulting from a lowered expression of the latter enzyme. Early studies
reported that purified CYP2B1 reconstituted in simple liposome exerted
the catalytic function in the absence of the CYP2B2 (Ryan et al.,
1979
). This observation seems to disagree with the above assumption. On
the other hand, it has been reported that the cytosolic domain of P450
is pulled into liposome by some kinds of phospholipid such as
phosphatidic acid (Ahn et al., 1998
). The secondary structures and the
function of the P450 enzyme deeply embedded into membrane are shown to
be different or enhanced from those in liposome consisting of one kind
of phospholipid (Ahn et al., 1998
). Thus, it seems likely that 1) the
CYP2B1 in endoplasmic reticulum membrane differs from that in
artificial liposome in its structure and function, and 2) the function
of the CYP2B1 is altered by interaction with the partner proteins as
well as by the composition of the phospholipid in membrane. To our
knowledge, functional cooperation of CYP2B1 and CYP2B2 has not been
reported. However, different electrophoretic mobility of CYP2B1 between (
/
) and (+/+) Qdj:SD rats may suggest the possible interaction of
2B1 and 2B2; that is, CYP2B1 accompanied by the coexpression of CYP2B2
in the (+/+) phenotype migrated faster than the CYP2B1 in (
/
) rats
that lacked CYP2B2 (see Fig. 2A). It has been suggested that CYP2B4 and
CYP1A2 interact with each other, affecting the function of the partner
(Backes et al., 1998
). In the latter case, CYP1A2-NADPH cytochrome P450
reductase interaction is facilitated by the binding of CYP2B4 to CYP1A2
(Backes et al., 1998
). A substrate-induced change in CYP2A6-CYP2E1
interaction has been reported (Tan et al., 1997
). Furthermore, Yamazaki
et al. (1997)
demonstrated the activation of the catalytic function of
CYP3A4 by CYP1A2. These data may support the possibility of the
CYP2B1-CYP2B2 interaction described above.
In conclusion, this study could not detect any serious mutations in the
exons of CYP2B2 gene, suggesting that this gene codes expressible protein, nor were any mutations detected at the PBRU, which
has been demonstrated to play a critical role in the PB induction
process. Although not conclusive, the available evidence suggests that
the Qdj:SD rats lack a PB-mediated induction of CYP2B2 may be
attributable either to mutations within a regulatory region of the gene
different from the PBRU or to the absence/lowered expression of
trans-acting factor(s) cooperatively involved in the
induction process.
We deeply thank Dr. Tsuneo Omura for valuable discussion and
encouragement. We are also indebted to Prof. Takeyoshi Miki, Graduate
School of Pharmaceutical Sciences, Kyushu University, for helpful
discussion and technical advice.
Accepted for publication August 2, 2000.
Received for publication May 31, 2000.
P450, cytochrome P450;
SD, Sprague-Dawley;
PB, phenobarbital;
CAR, constitutive androstane receptor;
RXR, retinoid X
receptor;
PBRE, PB-responsive element;
PBRU, PB-responsive unit;
PBREM, PB-responsive enhancer module;
UGT, UDP-glucuronosyltransferase;
PCR, polymerase chain reaction;
kbp, kilobase pair;
bp, base pair.